🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction Studies

Recruitingn/aAges any - 25 YearsAllAssistance Publique - Hôpitaux de Paris
NCT05772559 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Pediatric acute myeloid leukemias are disease with poor prognosis (overall survival of 60-75%) and high relapse rate of 35-45% require further understanding of the underlying biological mechanisms. The main objective of this study is to establish a biological collection to evaluate the genomic profiling of leukemic cells from primary blasts at diagnosis and/or relapse to improve identification of the main genetic hits involved in resistance and could predict a high risk of relapse. Other objectives include the study of bone marrow mesenchymal stem cells and ex vivo drug testing.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * 0-25 years old * Newly diagnosed de novo or secondary Acute Myeloid Leukemia (AML) or * Relapsed or refractory AML or * Patients with genetic predisposition to develop AML or * Patients without haematological malignancy nor AML genetic predisposition syndrome who undergo bone marrow aspirate as part of standard of care * Signed informed consent of parents for patients aged less than 18 years old or signed informed consent of the patient for patients aged 18 and over. Exclusion Criteria: * Refuse to participate * Chronic myeloid leukemia (CML) * Lack of health insurance (French social security) * Under protection (tutelle, curatelle or sauvegarde de justice) * Pregnancy or breastfeeding
💊

What it tests

  • Collection of blood sample of bone marrow (cohort 1)
  • Collection of blood sample of bone marrow (cohort 2 and 3)
📍

Where

28 sites
CHU Amiens Picardie site Sud
Amiens, France
CHU Angers
Angers, France
Hopital Minjoz
Besançon, France
CHU Pellegrin
Bordeaux, France
CHRU Morvan
Brest, France
CHU Caen
Caen, France
CHU Estaing
Clermont-Ferrand, France
CHU Francois Mitterand
Dijon, France

…and 20 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy